Abstract 1570
Background
Systemic chemotherapy (SC) has a negative effect on ovarian functions. The aim of this study is to investigate the effect of SC on anti-müllerian hormone (AMH) levels, antral follicle counts (AFC) and ovarian volumes (MOV) in patients with BC.
Methods
The demographic, clinical and pathological features of premenopausal breast cancer (BC) patients who were operated in the Istanbul Florence Nightingale Hospital were recorded. AMH levels, AFC and MOV measurements were performed before and after adjuvant SC in 3-month periods. The patients who did not have menstruel cycles for 6 months or longer had been classified as chemotherapy induced amenorrhea (CIA). The effects of different chemotherapy regimens on AMH, AFC and MOV in terms menstruel cycles resumption and CIA were investigated.
Results
Seventy one patients were eligible for the study, and median age of them was 38 years (ranged from 23 to 51 years). Median follow-up was 37 months (ranged from 20 to 51 months), CIA developed in 62% of patients. AMH, AFC, and MOV significantly decreased one year after SC (p < 0.0001). AMH before chemotherapy (median: 1,520 vs 0,755, p = 0.001), at the end of first year (median: 0,073 vs 0,010 ng/ml, p = 0.030) and pre-treatment AFC (median12 vs 4,50, p = 0.026) was lower in patients with CIA comparing those without CIA. In multivariate logistic regression analysis, AMH levels (OR:0.273, 95%: 0.102 – 0.733, p = 0.010) and AFC (OR: 1,180, 95% CI; 1,016-1,369, p = 0.030) before SC were the most valuable and earliest factors to predict CIA. There were no significant relationships between age of the patients (≤30vs>30 ), BMI (30vs> 30), SC regimen and number of cycles (4 vs > 4) and CIA (p > 0.05).Table:
254P muitivariet analyses with logistic regrettion for CIA
UNIVARIET | MULTIVARIET | ||||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | OR | 95% CI | ||||||
ER | 0,19 | 0,038 | - | 0,891 | 0,035 | 0,002 | 0,000 | - 0,111 | 0,002 |
HER 2 | 0.80 | 0,435 | - | 2,936 | 1,130 | ||||
ALND PERFORMED | 1,75 | 0,653 | - | 4,702 | 0,265 | ||||
AMH-1 | 0,64 | 0,454 | - | 0,914 | 0,014 | 0,273 | 0,102 | - 0,733 | 0,010 |
AMH-5 | 0,23 | 0,063 | - | 0,812 | 0,023 | 0,009 | 0,000 | - 0,754 | 0,037 |
AFC-1 | 0,87 | 0,780 | - | 0,961 | 0,007 | 0,735 | 0,572 | - 0,944 | 0,016 |
AFC-5 | 0,93 | 0,741 | - | 1,165 | 0,527 | ||||
MOV-1 | 1,00 | 0,987 | - | 1,021 | 0,686 | ||||
MOV-5 | 0,98 | 0,854 | - | 1,158 | 0,790 | ||||
TAXANE/W&İTHOUTTAXANE | 0,71 | 0,267 | - | 1,910 | 0,503 | ||||
TC/AC | 0,85 | 0,209 | - | 3,491 | 0,825 | ||||
AGE 35 | 4,66 | 1,613 | - | 13,498 | 0,004 | ||||
CHEMONUMBER | 0,24 | 0,080 | - | 0,766 | 0,017 | ||||
BMI 25 | 2,57 | 0,929 | - | 7,118 | 0,069 |
Conclusions
SC significantly decreases AMH and AFC values independently of chemotherapeutic agents in patients with BC. The low AMH levels and less AFC before SC may predict CIA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
İstanbul Demiroğlu Bilim University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3902 - The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment – single center experience in setting of no reimbursement in Poland (2011-2015)
Presenter: Agnieszka Badora-Rybicka
Session: Poster Display session 2
Resources:
Abstract
4733 - A Multicentre, International Neoadjuvant (NA), Randomized, Double-blind Phase III Trial comparing FULVESTRANT to a combination of FULVESTRANT and PALBOCICLIB in patients with operable Luminal Breast Cancer (SAFIA Trial)
Presenter: Jean-Marc Nabholtz
Session: Poster Display session 2
Resources:
Abstract
5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients
Presenter: Ulku Yalcintas Arslan
Session: Poster Display session 2
Resources:
Abstract
5943 - Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results
Presenter: Samir Beslija
Session: Poster Display session 2
Resources:
Abstract
1725 - Final results of scalp cooling for hair preservation: A single- institution prospective study.
Presenter: Dario Loparco
Session: Poster Display session 2
Resources:
Abstract
3713 - Adjuvant Systemic Therapy in Women with Early Breast Cancer and Intermediate Prosigna ROR Scores: Is Chemotherapy Use Declining? Evidence From a Large Practice
Presenter: Lowell Hart
Session: Poster Display session 2
Resources:
Abstract
818 - Management of early breast cancer in women over 90: A 10 year experience
Presenter: Emily Coffey
Session: Poster Display session 2
Resources:
Abstract
1141 - Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early- stage breast cancer.
Presenter: Daniel Reinhorn
Session: Poster Display session 2
Resources:
Abstract
2277 - Hepatitis B screening and incidence of flare among non-metastatic breast cancer patients treated with anthracyclines
Presenter: Zewen Zhang
Session: Poster Display session 2
Resources:
Abstract
2781 - Effect of denosumab on low bone mineral density in postmenopausal Japanese early breast cancer patients receiving aromatase nhibitors : 36-month results
Presenter: Koichi Sakaguchi
Session: Poster Display session 2
Resources:
Abstract